Streetbeat News

ASND

Ascendis Pharma A/S

Industry

Biotechnology

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapeutics for unmet medical needs. The company offers SKYTROFA for treating patients with growth hormone deficiency (GHD). It also develops TransCon Growth Hormone (hGH) for pediatric GHD in Japan; TransCon hGH for adults with GHD; TransCon parathyroid hormone for adult hypoparathyroidism; and TransCon CNP for pediatric achondroplasia. In addition, the company develops TransCon toll like receptors 7/8 agonist for intratumoral delivery; and TransCon IL-2 ß/g for systemic delivery. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Open

127.40

Mkt cap

7.1B

Volume

382K

High

127.99

P/E Ratio

-13.18

52-wk high

161.00

Low

124.11

Div yield

N/A

52-wk low

86.55

Ascendia Pharma shares are trading higher following the FDA approval of YORVIPATH for treating hypoparathyroidism in adults.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 12:13 pm

Trading for Ascendis Pharma (ASND) was halted and then resumed at 7:25 AM ET. The halt was due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:25 am

The FDA has approved Ascendis Pharma's Yorvipath (Palopegteriparatide; developed as TransCon PTH) for the treatment of hypoparathyroidism in adults. Ascendis is finalizing the manufacturing process for the U.S. market and expects the initial supply to be available in Q1 of 2025.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 11:05 am

Trading has been halted for a company at 6:55:00 a.m. ET due to pending news.

Portfolio Pulse from Benzinga Newsdesk

August 12, 2024 | 10:55 am

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past decade, delivering an average annual return of 49.72%. A $100 investment in ASND 10 years ago would be worth $5,869.77 today. The company's current market capitalization is $7.20 billion.

Portfolio Pulse from Benzinga Insights

August 09, 2024 | 4:30 pm

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past 10 years, delivering an average annual return of 54.04%. A $1000 investment in ASND 10 years ago would be worth $74,821.62 today. The company's current market capitalization is $7.92 billion.

Portfolio Pulse from Benzinga Insights

July 18, 2024 | 5:00 pm

Key stocks to watch include Macy's, Ascendis Pharma, LGI Homes, Ericsson, and GFL Environmental. Macy's received an increased buyout offer, Ascendis Pharma signed a distribution agreement, LGI Homes reported home closings, Ericsson announced an impairment charge, and GFL Environmental declared a dividend.

Portfolio Pulse from Avi Kapoor

July 05, 2024 | 3:01 pm

Pendopharm has partnered with Ascendis Pharma for the exclusive distribution of TransCon™ PTH in Canada. Pendopharm will handle regulatory approval and commercialization of the hypoparathyroidism treatment. Financial terms were not disclosed.

Portfolio Pulse from Benzinga Newsdesk

July 05, 2024 | 3:00 pm

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past 15 years, delivering an average annual return of 28.27%. A $1000 investment in ASND 15 years ago would be worth $45,483.28 today. The company's current market capitalization is $7.79 billion.

Portfolio Pulse from Benzinga Insights

July 03, 2024 | 2:30 pm

Ascendis Pharma (NASDAQ:ASND) has significantly outperformed the market over the past 15 years, delivering an average annual return of 27.98%. A $100 investment in ASND 15 years ago would be worth $4,051.86 today. The company's current market capitalization is $7.76 billion.

Portfolio Pulse from Benzinga Insights

June 26, 2024 | 3:02 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.